Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is willing and able to complete the micturition diary and questionnaires correctly~* Subject has symptoms of overactive bladder (urinary frequency and urgency with or without urge incontinence) for ≥ 3 months~* Subject experiences frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period~* Subject must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3-day micturition diary period~Exclusion Criteria:~* Subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control~* Subject has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Subject has an indwelling catheter or practices intermittent self-catheterization~* Subject has diabetic neuropathy~* Subject has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs~* Subject receives non-drug treatment including electro-stimulation therapy~* Subject has severe hypertension~* Subject has a known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other beta-adrenoreceptor (ß-AR) agonists, or lactose or any of the other inactive ingredients~* Subject has been treated with any investigational drug or device within 30 days (90 days in the UK)~* Subject had an average total daily urine volume \> 3000 mL as recorded in the 3-day micturition diary period~* Subject has serum creatinine \>150 umol/L, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2x upper limit of normal range (ULN), or gamma glutamyl transferase (γ-GT) \> 3x ULN~* Subject has a clinically significant abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
- Mirabegron 50 mg (Type: EXPERIMENTAL): Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
- Mirabegron 100 mg (Type: EXPERIMENTAL): Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
- Tolterodine SR 4 mg (Type: ACTIVE_COMPARATOR): Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).